The Latest Breaking News from Exscientia

“No matter how much data you have, human biology is still a mystery,” one analyst said.

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

Andrew Hopkins grew up on a council estate but described how he has since swapped that life for one in the prestigious city of Oxford after setting up his company, Exscientia

Andrew Hopkins has developed a biotech company called Exscientia which is revolutionising the industry

Exscientia plc (NASDAQ:EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist. The drug candidate is ​​co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ:EVO). Topline data confirmed Exscientia’s target product profile design, including potency, high receptor selectivity, and expected low brain exposure with…

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’